DISCLOSEDQuarterly
Dodge & Cox
Alnylam Pharmaceuticals Inc · NASDAQ
1,955,393 sh · $588.6M
Filed 30 Jun 2026SEC 13Fview source
BlackRock
13F filer
$2.32B
9,547,663 sh
Dodge & Cox
13F filer
$588.6M
1,955,393 sh
Two Sigma Investments
13F filer
$564.7M
1,875,937 sh
Bridgewater Associates
13F filer
$30.0M
99,584 sh
Soros Fund Management
13F filer
$2.0M
4,295 sh
Dodge & Cox
Alnylam Pharmaceuticals Inc · NASDAQ
1,955,393 sh · $588.6M
Bridgewater Associates
Alnylam Pharmaceuticals Inc · NASDAQ
99,584 sh · $30.0M
Two Sigma Investments
Alnylam Pharmaceuticals Inc · NASDAQ
1,875,937 sh · $564.7M
Bridgewater Associates
Alnylam Pharmaceuticals Inc · NASDAQ
106,592 sh · $35.3M
Two Sigma Investments
Alnylam Pharmaceuticals Inc · NASDAQ
1,992,577 sh · $659.3M
Dodge & Cox
Alnylam Pharmaceuticals Inc · NASDAQ
1,929,253 sh · $638.3M
Bridgewater Associates
Alnylam Pharmaceuticals Inc · NASDAQ
85,617 sh · $34.0M
Dodge & Cox
Alnylam Pharmaceuticals Inc · NASDAQ
1,964,415 sh · $781.1M
Two Sigma Investments
Alnylam Pharmaceuticals Inc · NASDAQ
616,120 sh · $245.0M
Soros Fund Management
Alnylam Pharmaceuticals Inc · NASDAQ
4,295 sh · $2.0M